Armored Dendritic Cell not checked
Shanghai Cell Therapy Group Co.,Ltd
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Armored dendritic cells are administered via multiple subcutaneous injections.”In the company’s words, NCT07479667 on ClinicalTrials.gov
- Tested for
- Solid Cancers, Adjuvant Therapy
- Main trialPhase 1
- “This study is a single-arm, open-label, single-administration dose-escalation study.”In the company’s words, NCT07479667 on ClinicalTrials.gov
Other drugs for Solid Cancers
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 31 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2028 | An Antibody-armored Dendritic Cell in Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026